First off -- apologies to those that couldnt access due to this latest (and seemingly) random requirement for Zoom to require a passcode all of a sudden. The direct session link should obviate that requirement (and usually does), but iof ever there is an issue I will ensure the passcode is set to "1234" as a default.

Anyway, it was an interesting chat. Archer is still a good ways off commercialisation, and although they are progressing things I'd expect investors have several years to wait (and a few more capital raisings) before any cash will start to come in the doors. Not that i'm throwing shade at Archer in any way -- just know that there's still quite a bit of risk associated with it.

But, as Simon said, with things like the biochip the challenge now is more engineering than the theory or science, and they seem to be confident of having something for regulators to consider in the next year or two.

Clearly, if they can make it all work there's a big opportunity to be captured. I'm just not sure how to handicap the odds.

Here's the transcript, and the recording is now on the meetings page.

AXE Transcript.pdf